Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hPLTs-05
- Development stage
- Preclinical
- Lead developer
- HemaCell Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
hPLTs-05 is a preclinical-stage cell therapy product being developed by HemaCell Therapeutics (Xue Ji Bio) for the treatment of thrombocytopenia. It represents a third-generation universal platelet technology engineered to lack human leukocyte antigen (HLA) antigens. This HLA-null approach is designed to enable platelet transfusions without the requirement for HLA matching between donor and recipient, thereby reducing the risk of alloimmunization and addressing immune-mediated platelet refractoriness in patients.
- Other names
- hPLTs-05 (universal platelet, no HLA)universal platelet (HLA-null)
Beyond the preview
Go deeper on hPLTs-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hPLTs-05.